Globus MedicalGMED.NValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, Globus Medical (GMED.N) trades at a P/E of 19.20x, P/B of 2.16x, P/S of 3.27x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 5th percentile over the trailing 10Y window (vs. 11th percentile over 3Y); P/B sits at the 11th percentile over the trailing 10Y window (vs. 37th percentile over 3Y); P/S sits at the 6th percentile over the trailing 10Y window (vs. 20th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 38th percentile within its industry and the 50th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 2.92%, ranking at the 97th percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 6.5 points of each other — a consistent signal from both angles. The P/E percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Shareholder returns here lean heavily on buybacks rather than cash dividends. Globus Medical operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NYSE: GMED · GMED
Want the full picture on whether Globus Medical (GMED.N) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 19.20 | ||||||
| P/B (MRQ) | 2.16 | ||||||
| P/S (TTM) | 3.27 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 2.92% |